Dataset Information

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

ABSTRACT:

Purpose

We tested the hypothesis that high plasma YKL-40 and IL-6 associate with pancreatic cancer and short overall survival.

Patients and methods

In all, 559 patients with pancreatic cancer from prospective biomarker studies from Denmark (n?=?448) and Germany (n?=?111) were studied. Plasma YKL-40 and IL-6 were determined by ELISAs and serum CA 19.9 by chemiluminescent immunometric assay.

Results

Odds ratios (ORs) for prediction of pancreatic cancer were significant for all biomarkers, with CA 19.9 having the highest AUC (CA 19.9: OR?=?2.28, 95% CI 1.97 to 2.68, p<0.0001, AUC?=?0.94; YKL-40: OR?=?4.50, 3.99 to 5.08, p<0.0001, AUC?=?0.87; IL-6: OR?=?3.68, 3.08 to 4.44, p<0.0001, AUC?=?0.87). Multivariate Cox analysis (YKL-40, IL-6, CA 19.9, age, stage, gender) in patients operated on showed that high preoperative IL-6 and CA 19.9 (dichotomized according to normal values) were independently associated with short overall survival (CA 19.9: HR?=?2.51, 1.22-5.15, p?=?0.013; IL-6: HR?=?2.03, 1.11 to 3.70, p?=?0.021). Multivariate Cox analysis of non-operable patients (Stage IIB-IV) showed that high pre-treatment levels of each biomarker were independently associated with short overall survival (YKL-40: HR?=?1.30, 1.03 to 1.64, p?=?0.029; IL-6: HR?=?1.71, 1.33 to 2.20, p<0.0001; CA 19.9: HR?=?1.54, 1.06 to 2.24, p?=?0.022). Patients with preoperative elevation of both IL-6 and CA 19.9 had shorter overall survival (p<0.005) compared to patients with normal levels of both biomarkers (45% vs. 92% alive after 12 months).

Conclusions

Plasma YKL-40 and IL-6 had less diagnostic impact than CA 19.9. Combination of pretreatment YKL-40, IL-6, and CA 19.9 may have clinical value to identify pancreatic cancer patients with the poorest prognosis.

SUBMITTER: Schultz NA

PROVIDER: S-EPMC3694124 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Schultz Nicolai A NA Christensen Ib J IJ Werner Jens J Giese Nathalia N Jensen Benny V BV Larsen Ole O Bjerregaard Jon K JK Pfeiffer Per P Calatayud Dan D Nielsen Svend E SE Yilmaz Mette K MK Holländer Niels H NH Wøjdemann Morten M Bojesen Stig E SE Nielsen Kaspar R KR Johansen Julia S JS

PloS one 20130626 6

<h4>Purpose</h4>We tested the hypothesis that high plasma YKL-40 and IL-6 associate with pancreatic cancer and short overall survival.<h4>Patients and methods</h4>In all, 559 patients with pancreatic cancer from prospective biomarker studies from Denmark (n = 448) and Germany (n = 111) were studied. Plasma YKL-40 and IL-6 were determined by ELISAs and serum CA 19.9 by chemiluminescent immunometric assay.<h4>Results</h4>Odds ratios (ORs) for prediction of pancreatic cancer were significant for al ...[more]

PMID: 23840582

Similar Datasets

Project description:BackgroundYKL-40 is a chitinase-like protein that, in cross-sectional clinical studies, has been associated with severe asthma and COPD in smokers.AimTo determine the longitudinal relation of circulating YKL-40 to levels and decline of lung function in the general population.MethodsWe used longitudinal data from up to 13 surveys from the population-based TESAOD study which was conducted in Tucson, Arizona between 1972 and 1996. In cross-sectional analyses, we also used data from 3 Spanish centers of the multicenter ECRHS study (ECRHS-Sp). Serum YKL-40 was measured at baseline in TESAOD and in survey 2 in ECRHS-Sp using ELISAs. Multivariate linear regression was used to test associations of serum YKL-40 to concomitant lung function. In TESAOD, random coefficients models were used to test associations of serum YKL-40 to subsequent decline of lung function.ResultsData on YKL-40 and lung function were available from 1088 TESAOD and 854 ECRHS-Sp adult participants (59% and 51% females; respectively). In adjusted multivariate meta-analyses, being in the highest YKL-40 quartile was associated cross-sectionally with significant deficits in FEV1 and FVC %predicted. In adjusted longitudinal analyses, TESAOD participants in the top YKL-40 quartile had an FEV1 decline that was 5 ml/yr (p = 0.05) faster than subjects in the third quartile, 5 ml/yr (p = 0.02) faster than subjects in the second quartile, and 10 ml/yr (p < 0.001) faster than subjects in the lowest YKL-40 quartile. These longitudinal effects were particularly strong in smokers and absent in never smokers. After adjusting for covariates, as compared with the other three quartiles combined, the top YKL-40 quartile was associated with a 9 ml/yr (p = 0.001) faster FEV1 decline among smokers, while no significant effects were found among never smokers (2 ml/yr, p = 0.35).ConclusionsCirculating YKL-40 is associated with levels and decline of lung function in the general population and may be a biomarker of susceptibility to the long-term effects of cigarette smoking.

Dataset Information

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Purpose

Patients and methods

Results

Conclusions

Publications

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets